Literature DB >> 9191524

Ultra-late recurrence (15 years or longer) of cutaneous melanoma.

H Tsao1, A B Cosimi, A J Sober.   

Abstract

BACKGROUND: Melanoma can remain clinically quiescent for decades before regional or distant recurrence appears. This protracted disease free interval challenges the concept of a "cure" for melanoma.
METHODS: To understand this prolonged dormancy better, the authors retrospectively studied patients who developed recurrent melanoma 15 years or longer after their initial diagnosis ("ultra-late" recurrence). These cases were identified from 2766 melanoma diagnoses available in the Cancer Registry at the Massachusetts General Hospital (MGH). Histologic features of the primary lesion were also included when possible.
RESULTS: Twenty cases were retrieved from the MGH database. There were equal numbers of women and men, although women were younger at the time of initial diagnosis (mean age of women: 29.8 years vs. 43.0 years for men). No patients had more than one primary cutaneous melanoma. The trunk was the most common primary site (35%), although there was no predominant anatomic localization. The average disease free interval was 17.3 years for women, 20.0 years for men, 18.1 years for patients with regional recurrence, and 19.0 years for patients with distant metastases. Distant recurrence was the most common type of recurrence (50% of women and 60% of men). The estimated probability of survival (5 years after recurrence) was 0.8 for regional disease and 0.2 for distant disease. With the available histologic records, it appears that almost all tumors were Clark Level III or IV with thicknesses ranging from 0.8-2.3 mm. In contrast to the published cases, this study did not find that women with lower extremity melanomas were at higher risk for developing ultra-late recurrence.
CONCLUSIONS: Ultra-late recurrence of melanoma, although uncommon, can occur in any patient without identifiable risk factors. Because many prognostically favorable melanomas (thin melanomas on extremities) can recur after prolonged disease free intervals, the possibility of delayed recurrence remains and must be kept in mind.

Entities:  

Mesh:

Year:  1997        PMID: 9191524

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  Fine-tuning anti-tumor immunotherapies via stochastic simulations.

Authors:  Giulio Caravagna; Roberto Barbuti; Alberto d'Onofrio
Journal:  BMC Bioinformatics       Date:  2012-03-28       Impact factor: 3.169

Review 2.  Does tumour dormancy offer a therapeutic target?

Authors:  Paul E Goss; Ann F Chambers
Journal:  Nat Rev Cancer       Date:  2010-11-04       Impact factor: 60.716

Review 3.  Mechanisms governing metastatic dormancy and reactivation.

Authors:  Filippo G Giancotti
Journal:  Cell       Date:  2013-11-07       Impact factor: 41.582

Review 4.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

Review 5.  Mechanisms of Cancer Cell Dormancy--Another Hallmark of Cancer?

Authors:  Albert C Yeh; Sridhar Ramaswamy
Journal:  Cancer Res       Date:  2015-09-09       Impact factor: 12.701

Review 6.  Treatment strategy for cutaneous malignant melanoma.

Authors:  Arata Tsutsumida; Hiroshi Furukawa; Yuhei Yamamoto; Tsuneki Sugihara
Journal:  Int J Clin Oncol       Date:  2005-10       Impact factor: 3.402

7.  Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression.

Authors:  A L Reid; M Millward; R Pearce; M Lee; M H Frank; A Ireland; L Monshizadeh; T Rai; P Heenan; S Medic; P Kumarasinghe; M Ziman
Journal:  Br J Dermatol       Date:  2012-11-15       Impact factor: 9.302

8.  Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up.

Authors:  Margherita Nannini; Guido Biasco; Maria Caterina Pallotti; Monica Di Battista; Donatella Santini; Paola Paterini; Alessandra Maleddu; Anna Mandrioli; Cristian Lolli; Maristella Saponara; Valerio Di Scioscio; Maurizio Zompatori; Fausto Catena; Pietro Fusaroli; Angelo Paolo Dei Tos; Maria Abbondanza Pantaleo
Journal:  Med Oncol       Date:  2011-01-22       Impact factor: 3.064

Review 9.  Long-term follow-up for melanoma patients: is there any evidence of a benefit?

Authors:  Natasha M Rueth; Kate D Cromwell; Janice N Cormier
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

Review 10.  Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review.

Authors:  Kate D Cromwell; Merrick I Ross; Yan Xing; Jeffrey E Gershenwald; Richard E Royal; Anthony Lucci; Jeffrey E Lee; Janice N Cormier
Journal:  Melanoma Res       Date:  2012-10       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.